The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations

被引：0
|
作者：
Kobayashi, Takashi [1 ]
Koizumi, Tomonobu [1 ]
Tanabe, Tsuyoshi [1 ]
Tsushima, Kenji [1 ]
Urushihata, Kazuhisa [1 ]
Yamamoto, Hiroshi [1 ]
Hanaoka, Masayuki [1 ]
Kubo, Keishi [1 ]
Koyama, Shigeru [2 ]
Ooura, Nariaki [3 ]
机构：
[1] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano 390, Japan
[2] Nagano Red Cross Hosp, Nagano, Japan
[3] Saku Cent Hosp, Saku, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S690 / S690
页数：1
相关论文
共 50 条
  • [1] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    [J]. EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
  • [2] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    [J]. BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
  • [3] Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
    Wheler, Jennifer J.
    Tsimberidou, Apostolia M.
    Falchook, Gerald S.
    Zinner, Ralph G.
    Hong, David S.
    Fok, Jansina Y.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) : 2167 - 2175
  • [4] The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib
    Li, Rui-chao
    Zheng, Li-jun
    Fang, Ming-hao
    Yu, Shi-ying
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2014, 29 (02): : E112 - E119
  • [5] DETECTING EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Hammoudeh, Z. A.
    Antonova, O.
    Staneva, R.
    Nikolova, D.
    Kyuchukov, Y.
    Penev, A.
    Mintchev, T.
    Koleva, V
    Hadjidekova, S.
    Toncheva, D.
    [J]. BALKAN JOURNAL OF MEDICAL GENETICS, 2018, 21 (01) : 13 - 17
  • [6] A single centre experience of erlotinib in unselected and wild type EGFR patients with non small cell lung cancer
    Walter, H. S.
    Ahmed, S. I.
    [J]. LUNG CANCER, 2013, 79 : S7 - S7
  • [7] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
  • [8] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    [J]. ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [9] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [10] Association of epithelial to mesenchymal transition with efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild type
    Ren, Shengxiang
    Su, ChunXia
    Chen, Xiaoxia
    Li, Jiayu
    Li, Bing
    Li, Xuefei
    Zhou, Caicun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345